web analytics
Hutchison China Meditech

Based on an update from our preferred small cap tip sheet, Small Company Share Watch, we passed an eye over an old Investor Trader favourite, Hutchison China Meditech. We liked what we saw. Huthcison is an interesting proposition on many levels. Its focus is on researching, developing, manufacturing and supplying health-oriented consumer products – primarily to the Chinese markets – which it achieves through three divisions: a healthcare division, a research and development division and a consumer products division. It's this mix of underlying profitability from a flourishing healthcare division (the latest interims (pdf) showed revenues up 25% and a 97% growth...

Cherry Picking Profitable AIM Shares

A couple of weeks ago now - prior to a little mid-summer rest and relaxation - I penned a post (with one foot out the door) in which I fleetingly mentioned the fact we'd liquidated a number of holdings and topped up on one in particular I thought a little over-sold. There wasn't any great financial nous behind that decision, no fundamental or technical analysis. Charts weren't poured over, ratios weren't examined, calendars of upcoming financial events were not consulted. I got what's know in bad economic times as the heebee-jeebies, the financial jitters. It's a desire, neigh necessity, to take what...

13 UK Shares on AIM

You'll have to excuse this post, it's a little self indulgent and - as Lucy from Entertainment One has kindly pointed out - incorrectly titled, since Entertainment One moved to the main board in July 2010. I wanted to throw the recent (three months in this case) charts of all our holdings together in the one place so I can get a bit of a feel of what's looking good (and what's looking not so good) technically speaking as we punch on in to 2011. Usually I'd do this sort of thing without posting it but what the heck. So with a...

Sale – Hutchison China Meditech

The first of our eight transactions for late December 2010 was the sale of another tranche of Hutchison China Meditech. We bought in to HCM.L in July 2010, taking up 520 shares at £3.14 a share. We first took profit earlier in December selling 220 shares at £5.10 and then again with this more recent sale of 100 shares at £4.95. Our original outlay (excluding dealer costs) was £1,632.80 and our two December sales have netted £1,122.00 and £495.00 respectively or £1,617.00 in total. In effect we've re-couped our original investment and we still own 200 shares which are currently trading at five...

Sale – Hutchison China Meditech

With a handful of shares on my must-have before Christmas list we chopped the top off a few of our more profitable holdings last week. This is never easy to do, especially when you know there's more to come. I'm a big fan of letting the good ones run (unfortunately I've been known to let the bad ones run too - see Cosalt - though I'm assured there's good news to come...

Sale – Renesola

With last rites being performed on Renesola's AIM listing before shifting their focus solely to their New York Stock Exchange listing, last Thursday 4th November we sold off our final tranche of 500 shares of our portfolio stalwart for 4.0150 pence a share and a total return of £2,007.50 before dealer costs. We were averaged into Renesola at £1.12 a share so we took a 350% profit on Renesola this time round. Renesola has always been good to me over the years. Taking me up toward the giddy heights of £7 before I lost my nerve and smacked the sell key...